One US-made drug treats congenital syphilis, and the country is running short

The United States is facing a critical shortage of Bicillin L-A, the sole first-line treatment for congenital syphilis, a condition where syphilis is passed from mother to baby during pregnancy. This shortage comes as cases of congenital syphilis have surged, highlighting a significant public health concern. The voluntary recall by Pfizer, the manufacturer, has exacerbated the issue, raising alarms about maternal and infant health. This situation underscores the need for urgent action to ensure the availability of essential medications for treating syphilis and preventing its transmission to newborns.